These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. Agabiti Rosei E; Salvetti M High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901 [TBL] [Abstract][Full Text] [Related]
5. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
9. The efficacy of anti-PCSK9 antibodies: Results from recent trials. Gouni-Berthold I Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. Ridker PM; Revkin J; Amarenco P; Brunell R; Curto M; Civeira F; Flather M; Glynn RJ; Gregoire J; Jukema JW; Karpov Y; Kastelein JJP; Koenig W; Lorenzatti A; Manga P; Masiukiewicz U; Miller M; Mosterd A; Murin J; Nicolau JC; Nissen S; Ponikowski P; Santos RD; Schwartz PF; Soran H; White H; Wright RS; Vrablik M; Yunis C; Shear CL; Tardif JC; N Engl J Med; 2017 Apr; 376(16):1527-1539. PubMed ID: 28304242 [TBL] [Abstract][Full Text] [Related]
11. [PCSK9 inhibitors; who benefits from these new cholesterol-lowering drugs?]. Gulpen AJW; Claessen RJM; Vanmolkot FHM Ned Tijdschr Geneeskd; 2020 Jan; 164():. PubMed ID: 32186821 [TBL] [Abstract][Full Text] [Related]
12. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Della Badia LA; Elshourbagy NA; Mousa SA Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571 [TBL] [Abstract][Full Text] [Related]
13. [PCSK9 inhibitors (PCSK9i), a new opportunity for cardiovascular prevention: clinical and regulatory aspects and access to therapy.]. Arca M Recenti Prog Med; 2019 Sep; 110(9):401-411. PubMed ID: 31593176 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL; J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591 [TBL] [Abstract][Full Text] [Related]
15. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors. Scherer DJ; Nelson AJ; Psaltis PJ; Nicholls SJ Intern Med J; 2017 Aug; 47(8):856-865. PubMed ID: 28401639 [TBL] [Abstract][Full Text] [Related]
16. PCSK9 in cholesterol metabolism: from bench to bedside. Reiss AB; Shah N; Muhieddine D; Zhen J; Yudkevich J; Kasselman LJ; DeLeon J Clin Sci (Lond); 2018 Jun; 132(11):1135-1153. PubMed ID: 29895529 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease. Okere AN; Serra C Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279 [TBL] [Abstract][Full Text] [Related]
18. [Consensus statement of professional associations on prescribing of PCSK9-inhibitors]. Češka R; Táborský M; Vrablík M Vnitr Lek; 2019; 64(12):1131-1136. PubMed ID: 30704246 [TBL] [Abstract][Full Text] [Related]